MGX$1.86
Chart
Performance
Key Stats
AI MGX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldMetagenomi (MGX) shows potential in the genetic medicine space with promising partnerships. However, significant financial losses, negative earnings, and current weak technicals suggest a cautious approach. Investors should monitor upcoming earnings and clinical trial progress.
Thematic
Metagenomi operates in the high-growth genetic medicine sector, driven by advancements in genome editing. Partnerships with Ionis Pharmaceuticals and Affini-T Therapeutics provide validation, but the overall market sentiment for early-stage biotech can be volatile.
Fundamental
Metagenomi exhibits significant operating losses and negative net income, common for early-stage biotech but concerning given its market capitalization. While revenue is growing, it remains low relative to expenses. The balance sheet has substantial cash but also significant debt. The lack of a positive P/E ratio reflects its current unprofitability.
Technical
The stock price has experienced a significant decline over the past year. Current technical indicators, including moving averages and RSI, suggest a bearish trend with limited immediate upside potential. The stock is trading well below its 52-week high.
| Factor | Score |
|---|---|
| Genetic Medicine Advancement | 85 |
| Partnerships & Collaborations | 80 |
| Clinical Trial Progress (Implied) | 70 |
| Biotech Sector Volatility | 65 |
| Market Adoption of Gene Editing | 75 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 60 |
| Balance Sheet Health | 70 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 25 |
| Momentum | 45 |
| Volume Confirmation | 50 |
| Support & Resistance | 30 |
| Performance | 20 |
AI Investing Checklist
Powered by LiveAIBullish Points (8)
Revenue Growth Potential
The company has demonstrated significant revenue growth, with an increase from $0.24M in 2021 to $52.30M in 2024. This strong top-line expansion suggests increasing market adoption or product success.
Improving Cash Position
Cash and cash equivalents have significantly increased from $39.30M in Q4 2021 to $27.39M in Q4 2024, and even higher in Q1 2025 to $34.44M, indicating a strengthening ability to fund operations and growth initiatives.
Bearish Points (10)
Consistent Net Losses
The company has consistently reported net losses, with net income ranging from -$21.44M in 2021 to -$78.06M in 2024. This indicates that the company is not yet profitable.
Negative P/E Ratio
The Price-to-Earnings (P/E) ratio is negative across all reported periods (e.g., -1.7 in 2024), which is a direct consequence of the company's net losses and makes traditional valuation comparisons challenging.
Calendar
August 2025
14
Next Earnings Date
H: $-0.51
A: $-0.61
L: $-0.72
H: 12.10M
A: 7.72M
L: 2.50M
Profile
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Seasonals
Price Target
10.75 USD
The 39 analysts offering 1 year price forecasts for MGX have a max estimate of 16.00 and a min estimate of 7.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
One of the world's largest lithium producers, directly competing and operating in the same core market as MGX Minerals Inc.'s lithium interests.
Weight: 97
A leading global producer of lithium and specialty chemicals, a direct competitor and peer in the critical minerals sector.
Weight: 96
A pure-play lithium chemicals producer, showcasing the specialized market focus relevant to MGX Minerals Inc.'s endeavors.
Weight: 95
Developing significant lithium projects, including Thacker Pass in the U.S., representing a key player in North American lithium supply.